http://purduepharma.com/news-media/2017/03/fda-approves-symproic-naldemedine-once-daily-tablets-c-ii-for-the-treatment-of-opioid-induced-constipation-in-adults-with-chronic-non-cancer-pain/
As I have previously mentioned, the Purdue/Shionogi tie-up on naldemedine reduces the chances that Purdue will partner with NKTR on 181. I would think that NKTR, AZN and Daiichi Sankyo will want Movantik to be the preferred remedy for OIC caused by 181. It was clear from the 181 call that Movantik was made available to any trial participant who experienced OIC while on the trial. This likely contributed to the participants' favorable "global impression of change" (highly stat sig) from treatment with 181.